Antoine Pharma SRL
Antoine Pharma reported total assets of €1.46m at the end of the 2025 financial year (annual accounts filed with the NBB on 29 May 2026).
The score of Antoine Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -78 % Total assets +6 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Antoine Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 106,892 € | ||||
| Equity | 60,552 € | ||||
| Cash | 151,963 € | ||||
| EBITDA | 149,192 € | ||||
| Total assets | €1.46m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 May 2026
- Year ended 31 Dec 2024filed on 19 Jun 2025
- Year ended 31 Dec 2023filed on 25 Jun 2024
- Year ended 31 Dec 2022filed on 31 May 2023
- Year ended 31 Dec 2021filed on 09 Jun 2022
Antoine Pharma's financial analysis
- Solvency4.2%sector median: 37.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Antoine Pharma
Antoine Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0732.705.039
- VAT number
- BE0732705039
- Peppol
- Registered · 0208:0732705039 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Aug 2019
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 29 May 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Antoine Pharma (SRL) has been based in Ixelles since 2019, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 106,892 € and equity of 60,552 €; its revenue is not published. Its solvency stands at 4.2%, below the median of its sector (37.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Antoine Pharma
Companies in the same business, of comparable size and area, outside its group.
- GeDP PHARMA Retail sale of pharmaceutical products Knokke-Heist · balance sheet €1.69m
- Digitale Retail sale of pharmaceutical products Etterbeek · balance sheet €1.38m
- Saarbach Dino Retail sale of pharmaceutical products Chaudfontaine · balance sheet €1.44m
- Apharmat Retail sale of pharmaceutical products Antwerp · balance sheet €1.42m
- Apotheek Vanoost Retail sale of pharmaceutical products Aalst · balance sheet €1.37m
- Duchi-Naert Retail sale of pharmaceutical products Harelbeke · balance sheet €1.52m
- Pharma OZ Retail sale of pharmaceutical products Charleroi · balance sheet €1.23m
- Pharmakes Retail sale of pharmaceutical products Ypres · balance sheet €1.57m
Frequently asked questions about Antoine Pharma
What is the revenue of Antoine Pharma?
Antoine Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Antoine Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0732705039 for Antoine Pharma, if the company is VAT-registered. Its company number (CBE) is 0732.705.039.
Where is the registered office of Antoine Pharma?
According to the CBE register, the registered office of Antoine Pharma is in 1050 Ixelles.
What is the equity of Antoine Pharma?
At the close of the 2025 financial year, the equity of Antoine Pharma amounts to 60,552 €, a solvency of 4.2% of total assets.
Who manages Antoine Pharma?
The register lists 2 active mandates at Antoine Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Antoine Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →